» Articles » PMID: 12773508

Prostaglandin E2 Modulates Dendritic Cell Function Via EP2 and EP4 Receptor Subtypes

Overview
Journal J Leukoc Biol
Date 2003 May 30
PMID 12773508
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

We have reported previously that PGE(2) inhibits dendritic cells (DC) functions. Because E prostanoid receptor (EPR) subtypes involved in this action are unknown, expression and functions of these receptors were examined in DC. Western blot and flow cytometry analyses showed that all EPRs were coexpressed in DC. In a dose-dependent manner, lipopolysaccharide (LPS) enhanced EP(2)R/EP(4)R but not EP(1)R/EP(3)R expressions. NS-398, a cyclooxygenase (COX)-2-selective inhibitor, suppressed LPS-enhanced EP(2)R/EP(4)R expression, suggesting that COX-2-issued prostaglandin E(2) (PGE(2)) modulates DC function through stimulation of specific EPR subtypes. Using selective agonists, we found that butaprost, an EP(2)R agonist, and PGE(1) alcohol, an EP(2)R and EP(2)R/EP(4)R agonist, inhibited major histocompatibility complex class II expression and enhanced interleukin-10 production from DC. However, no effect was observed with sulprostone and 17-phenyl-omega-trinor-PGE(2), selective agonists for EP(1)R and EP(1)R/EP(3)R, respectively. Treatment of DC with dibutyryl cyclic adenosine monophosphate (cAMP), an analog of cAMP, mimics PGE(2)-induced, inhibitory effects. Taken together, our data demonstrate that EP(2)R/EP(4)R are efficient for mediating PGE(2)-induced modulation of DC functions.

Citing Articles

Research progress on nonsteroidal anti-inflammatory drugs in the treatment of pituitary neuroendocrine tumors.

Li J, Shi X, Tang T, Zhou M, Ye F Front Pharmacol. 2024; 15:1407387.

PMID: 39135798 PMC: 11317762. DOI: 10.3389/fphar.2024.1407387.


TXA2 attenuates allergic lung inflammation through regulation of Th2, Th9, and Treg differentiation.

Li H, Bradbury J, Edin M, Gruzdev A, Li H, Graves J J Clin Invest. 2024; 134(9).

PMID: 38483511 PMC: 11060738. DOI: 10.1172/JCI165689.


EP2 and EP4 blockade prevents tumor-induced suppressive features in human monocytic myeloid-derived suppressor cells.

Cuenca-Escalona J, Subtil B, Garcia-Perez A, Cambi A, de Vries I, Florez-Grau G Front Immunol. 2024; 15:1355769.

PMID: 38343540 PMC: 10853404. DOI: 10.3389/fimmu.2024.1355769.


Trinity of inflammation, innate immune cells and cross-talk of signalling pathways in tumour microenvironment.

Attiq A, Afzal S Front Pharmacol. 2023; 14:1255727.

PMID: 37680708 PMC: 10482416. DOI: 10.3389/fphar.2023.1255727.


The impact of lipids on the cancer-immunity cycle and strategies for modulating lipid metabolism to improve cancer immunotherapy.

Zheng M, Zhang W, Chen X, Guo H, Wu H, Xu Y Acta Pharm Sin B. 2023; 13(4):1488-1497.

PMID: 37139414 PMC: 10149904. DOI: 10.1016/j.apsb.2022.10.027.